Table 3.
Serologic analysis of the anti-N-protein immune response obtained by reaction of the yeast-displayed fusion proteins with sera from convalescent SARS patients.
| Sera1 | Reactivity based on RAYS ratio2 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Full-length N3 (1–422) | NT1 (1–69) | NT2 (68–120) | NT3 (119–213) | NT4 (212–341) | NT5 (337–422) | NND13 (1–120) | NND14 (1–213) | NNDC1 (68–213) | NNDC2 (214–422) | ||||||||||
| Case 1 | +/+ | +/+ | −/− | −/+ | −/− | +/+ | +/− | +/+ | +/+ | −/− | |||||||||
| Case 2 | +/+ | +/+ | −/− | −/− | −/− | −/+ | +/+ | +/+ | +/− | −/− | |||||||||
| Case 3 | +/+ | +/− | −/− | −/+ | −/− | +/+ | −/− | +/+ | +/+ | +/− | |||||||||
| Case 4 | +/+ | +/+ | −/− | −/− | +/− | +/+ | +/− | +/+ | +/+ | −/+ | |||||||||
| Case 5 | +/+ | −/+ | −/− | −/+ | −/− | +/− | −/+ | +/+ | −/− | −/+ | |||||||||
| Case 6 | +/+ | +/+ | −/− | +/+ | −/− | +/+ | −/− | +/+ | +/+ | −/− | |||||||||
| Case 7 | +/+ | +/+ | −/− | −/− | −/− | +/+ | +/+ | +/+ | +/− | −/− | |||||||||
| Case 8 | +/+ | +/+ | −/− | +/+ | +/− | −/+ | −/− | +/+ | +/+ | −/− | |||||||||
| Case 9 | +/+ | −/+ | −/− | −/− | −/− | +/+ | +/− | +/+ | +/+ | −/+ | |||||||||
| Case 10 | +/+ | +/+ | −/− | −/+ | −/− | +/+ | −/+ | +/+ | +/+ | −/− | |||||||||
| Case 11 | +/+ | +/+ | −/− | +/+ | −/− | −/+ | +/+ | +/+ | +/+ | −/− | |||||||||
| Case 12 | +/+ | +/+ | −/− | −/− | −/− | +/+ | −/− | +/+ | +/+ | −/− | |||||||||
| Case 13 | +/+ | +/+ | −/− | −/+ | −/− | +/+ | −/+ | +/+ | +/+ | +/− | |||||||||
| Case 14 | +/+ | +/− | −/− | −/− | −/− | +/+ | +/− | −/+ | +/− | −/− | |||||||||
| Case 15 | +/+ | −/+ | −/− | −/+ | +/− | +/+ | −/+ | +/+ | +/+ | −/− | |||||||||
| Case 16 | +/+ | +/+ | −/− | −/+ | −/− | +/+ | +/− | +/+ | +/+ | −/− | |||||||||
| Case 17 | +/+ | +/− | −/− | −/+ | −/− | +/− | −/− | +/+ | +/+ | −/− | |||||||||
| Case 18 | +/+ | +/+ | −/− | −/+ | −/− | +/+ | +/+ | +/+ | +/− | −/− | |||||||||
| Case 19 | +/+ | +/− | −/− | −/+ | −/− | +/+ | +/− | +/+ | +/+ | −/− | |||||||||
| Case 20 | +/+ | +/+ | −/− | −/− | −/− | +/+ | −/− | +/+ | +/+ | −/− | |||||||||
| Pooled4 | +/+ | +/+ | −/− | −/+ | −/− | +/+ | +/+ | +/+ | +/+ | −/− | |||||||||
The sera from individual convalescent SARS patients were numbered case 1 to 20.
RAYS ratios before/after denaturation of the particular displayed fusion protein: +, RAYS ratio ≥2 (positive); −, RAYS ratio <2 (negative). The RAYS ratio was calculated as described in the text.
Ten proteins, including the full-length N protein and its fragments displayed on the yeast EBY100 cell surface before and after denaturation, were used in this assay. The numbers in parentheses represent the amino acid numbers of the start and stop positions on the N protein.
Pooled sera was obtained by mixing the sera from SARS cases 21–40.